No Data
No Data
Analysts Offer Insights on Healthcare Companies: Daré Bioscience (DARE), Legend Biotech (LEGN) and Singular Genomics Systems (OMIC)
Legend Expects to Log Profit in 2026
Nasdaq-listed biotechnology company Legend Biotech expects to log a profit in 2026, according to a Monday filing by parent company Genscript Biotech (HKG:1548) on the Hong Kong bourse. Legend Biotech
Legend Biotech Price Target Raised to $86.00/Share From $85.00 by RBC Capital
Legend Biotech Price Target Raised to $86.00/Share From $85.00 by RBC Capital
Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Green Thumb Industries (OtherGTBIF) and OmniAb (OABI)
Legend Biotech's Loss Narrows in Q1 as Revenue Surges
Genscript Biotech's (HKG:1548) Nasdaq-listed subsidiary Legend Biotech reported a loss of $59.8 million, or $0.16 per share, in the first quarter, down from $112.1 million, or $0.34 per share, a year
Scotiabank Sticks to Their Buy Rating for Legend Biotech (LEGN)
Ginvest : Thank you for the timely info
Srav Reddy : $X4 Pharmaceuticals (XFOR.US)$ announcement was early on 29/4. But price receded. This is surprising to me.